Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by Lifeworks Advisors LLC

Lifeworks Advisors LLC reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 42.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,523 shares of the biopharmaceutical company's stock after selling 9,846 shares during the period. Lifeworks Advisors LLC's holdings in Bristol Myers Squibb were worth $825,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of BMY. Pinney & Scofield Inc. purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $26,000. Global Wealth Strategies & Associates grew its holdings in shares of Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Transce3nd LLC acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Bristol Myers Squibb in the first quarter valued at approximately $31,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY traded down $0.51 during midday trading on Friday, hitting $48.44. The company had a trading volume of 11,836,611 shares, compared to its average volume of 12,210,974. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The firm has a market capitalization of $98.57 billion, a price-to-earnings ratio of 18.14, a price-to-earnings-growth ratio of 2.56 and a beta of 0.36. The business has a 50-day simple moving average of $47.67 and a two-hundred day simple moving average of $52.64. Bristol Myers Squibb Company has a twelve month low of $44.00 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period last year, the company posted ($4.40) EPS. The company's revenue was down 5.6% on a year-over-year basis. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.12%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of recent research reports. Morgan Stanley cut their price objective on Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a research report on Thursday, July 10th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. UBS Group dropped their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Finally, Jefferies Financial Group dropped their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $58.53.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.